These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 33296969)

  • 1. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
    Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
    Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
    Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
    J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
    [No Abstract]   [Full Text] [Related]  

  • 6. Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J
    PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
    Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
    Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
    Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities.
    Chataway J; Murphy N; Khurana V; Schofield H; Findlay J; Adlard N
    Curr Med Res Opin; 2021 Jun; 37(6):995-1004. PubMed ID: 33733976
    [No Abstract]   [Full Text] [Related]  

  • 10. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.
    Tutuncu M; Tang J; Zeid NA; Kale N; Crusan DJ; Atkinson EJ; Siva A; Pittock SJ; Pirko I; Keegan BM; Lucchinetti CF; Noseworthy JH; Rodriguez M; Weinshenker BG; Kantarci OH
    Mult Scler; 2013 Feb; 19(2):188-98. PubMed ID: 22736750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antioxidant parameters of multiple sclerosis patients' serum according to the disease course.
    Nowak-Kiczmer M; Niedziela N; Zalejska-Fiolka J; Adamczyk-Sowa M
    Mult Scler Relat Disord; 2023 Sep; 77():104875. PubMed ID: 37454567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
    Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Employment and absenteeism in working-age persons with multiple sclerosis.
    Salter A; Thomas N; Tyry T; Cutter G; Marrie RA
    J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.
    Tremlett H; Zhao Y; Devonshire V;
    J Neurol; 2009 Mar; 256(3):374-81. PubMed ID: 19308306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Salter A; Thomas NP; Tyry T; Cutter GR; Marrie RA
    Mult Scler; 2018 Jun; 24(7):951-962. PubMed ID: 28524746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
    Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
    Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.